论文部分内容阅读
目的监测广东高州市23价肺炎多糖疫苗副反应发生情况,便于指导今后的处理工作。方法对2岁以上体弱儿童和50岁以上老人在知情、同意、自愿的原则下,统一接种成都生物制品研究所生产的23价多糖肺炎疫苗。接种后30d内以填卡方式进行副反应的跟踪随访监测,主要监测局部反应和全身反应,30d后回收监测卡进行分析。结果共观察接种1166人,回收有效监测卡1016张,年龄最小2岁,最大72岁,19张卡有副反应报告,轻微副反应发生率为1.87%,其中局部副反应发生率为1.18%,全身副反应发生率为1.97%,未见严重和罕见副反应。结论成都生物制品研究所生产的23价肺炎球菌多糖疫苗安全性高,接种后副反应发生率低。
Objective To monitor the occurrence of 23-valent pneumonia polysaccharide vaccine side effects in Gaozhou City of Guangdong Province so as to guide future treatment. Methods The 23-valent polysaccharide pneumonia vaccine produced by Chengdu Institute of Biological Products was uniformly inoculated into infants under 2 years of age and over 50 years of age on the principle of informed consent and voluntary consent. Follow-up monitoring of side effects was carried out within 30 days after inoculation. The local reactions and systemic reactions were mainly monitored. After 30 days, monitoring cards were collected for analysis. Results A total of 1,166 people were vaccinated, 1016 valid surveillance cards were recovered, the youngest was 2 years old, the oldest was 72 years old, and 19 cards were reported with side effects. The incidence of minor side effects was 1.87%, and the incidence of local side effects was 1.18% The incidence of systemic side effects was 1.97%, no serious and rare side effects. Conclusion The 23-valent pneumococcal polysaccharide vaccine produced by Chengdu Institute of Biological Products is safe and has a low incidence of side effects after inoculation.